Table 3 Characteristics associated with research participation

 Gender

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Male

5,983

64.0

(ref)

(ref)

  Female

6,699

60.9

0.87

0.82 – 0.93

< 0.001

0.91

0.82 – 1.00

0.06

 Age group

  16 – 25

67

68.4

1.32

0.86 – 2.04

0.20

1.48

0.80 – 2.71

0.21

  26 – 35

229

72.2

1.60

1.24 – 2.06

< 0.001

1.39

1.03 – 1.86

0.03

  36 – 50

1,497

66.6

1.24

1.12 – 1.37

< 0.001

1.23

1.03 – 1.47

0.02

  51 – 65

4,774

65.7

1.21

1.13 – 1.30

< 0.001

1.15

1.02 – 1.29

0.02

  66 – 75

4,172

61.3

(ref)

(ref)

  76+

1,579

54.6

0.77

0.71 – 0.85

< 0.001

0.79

0.71 – 0.88

< 0.001

 Ethnicity

  White

11,705

62.7

(ref)

(ref)

  Mixed

88

66.7

1.17

0.81 – 1.67

0.41

0.77

0.48 – 1.24

0.28

  Asian/Asian British

254

59.1

0.84

0.69 – 1.02

0.08

0.71

0.54 – 0.92

0.01

  Black/Black British

201

55.7

0.76

0.61 – 0.94

0.01

0.63

0.47 – 0.83

0.001

  Other

68

63.6

1.02

0.69 – 1.53

0.91

0.73

0.43 – 1.26

0.26

 Long-standing conditions ^b

  None

8,127

63.7

  Deafness/hearing impairment

991

60.4

0.92

0.83 – 1.03

0.13

1.04

0.92 – 1.19

0.54

  Blindness/partially sighted

220

63.4

1.06

0.85 – 1.33

0.60

1.09

0.78 – 1.52

0.61

  Physical condition

1,519

61.2

0.92

0.84 – 1.01

0.06

0.91

0.82 – 1.01

0.08

  Learning disability

45

54.9

0.73

0.47 – 1.15

0.17

0.66

0.33 – 1.35

0.26

  Mental health condition

219

61.7

0.97

0.78 – 1.21

0.80

0.99

0.71 – 1.40

0.99

  Long-standing illness ^c

1,348

59.4

0.86

0.78 – 0.94

0.001

0.86

0.77 – 0.97

0.01

 Tumour group

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Brain/CNS

171

67.1

1.63

1.24 – 2.15

0.001

1.42

0.91 – 2.22

0.12

  Breast

2,769

56.9

(ref)

(ref)

  Colorectal / Lower GI

1,709

64.0

1.33

1.21 – 1.47

< 0.001

1.34

1.14 – 1.59

0.001

  Gynaecological

621

61.1

1.19

1.04 – 1.37

0.01

1.30

1.06 – 1.59

0.01

  Haematological

2,753

71.7

1.95

1.78 – 2.14

< 0.001

1.98

1.65 – 2.38

< 0.001

  Head and Neck

430

65.3

1.43

1.20 – 1.70

<0.001

1.28

0.96 – 1.71

0.09

  Lung

864

59.9

1.17

1.03 – 1.32

0.01

1.14

0.95 – 1.37

0.15

  Other

547

65.7

1.49

1.27 – 1.74

< 0.001

1.38

1.09 – 1.74

0.01

  Prostate

1,080

60.5

1.18

1.05 – 1.32

0.004

1.15

0.94 – 1.41

0.18

  Sarcoma

161

70.3

1.86

1.38 – 2.50

< 0.001

1.58

0.91 – 2.76

0.10

  Skin

183

57.9

1.07

0.85 – 1.36

0.56

1.00

0.64 – 1.56

0.99

  Upper GI

819

58.9

1.10

0.98 – 1.25

0.12

1.04

0.86 – 1.26

0.70

  Urological

575

54.9

0.91

0.79 – 1.04

0.17

0.97

0.79 – 1.20

0.80

 Time since 1 ^st treatment

  < 1 year

7,355

60.1

(ref)

(ref)

  1–5 years

3,820

66.8

1.31

1.23 – 1.40

< 0.001

1.22

1.10 – 1.34

< 0.001

  > 5 years

1,199

67.3

1.39

1.25 – 1.55

< 0.001

1.25

1.09 – 1.44

0.002

 Trust type

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Small acute

825

59.6

1.02

0.90 – 1.15

0.84

1.02

0.83 – 1.23

0.92

  Medium acute

2,329

59.2

0.99

0.91 – 1.08

0.79

0.96

0.83 – 1.12

0.62

  Large acute

3,465

59.3

(ref)

(ref)

  Specialist

1,109

69.1

1.55

1.37 – 1.75

< 0.001

1.40

1.16 – 1.70

0.001

  Teaching

4,954

65.3

1.30

1.21 – 1.40

< 0.001

1.31

1.12 – 1.52

0.001

 Foundation status

  No

5,254

61.2

(ref)

(ref)

  Yes

7,428

63.1

1.08

1.02 – 1.14

0.01

1.02

0.91 – 1.15

0.69

 Location

  Outside London

10,170

61.4

  London

2,512

66.5

1.25

1.16–1.35

< 0.001

1.12

0.95 – 1.31

0.17